| Dr Charles K Kirkland, DO | |
|
812 Gorman Ave, Elkins, WV 26241-3181 | |
| (304) 636-3300 | |
| (304) 637-3435 |
| Full Name | Dr Charles K Kirkland |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 812 Gorman Ave, Elkins, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578540001 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 1015 (West Virginia) | Primary |
| Entity Name | West Virginia University Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275504508 PECOS PAC ID: 1052224565 Enrollment ID: O20031111000207 |
News Archive
For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected.
Catching cancer early can make all the difference for successful treatment. A common screening practice measures tumor growth with X-ray computed tomography, which takes a series of cross-section images of the body.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.
BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
› Verified 5 days ago
| Entity Name | Davis Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619964806 PECOS PAC ID: 3072418540 Enrollment ID: O20040107000438 |
News Archive
For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected.
Catching cancer early can make all the difference for successful treatment. A common screening practice measures tumor growth with X-ray computed tomography, which takes a series of cross-section images of the body.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.
BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
› Verified 5 days ago
| Entity Name | Jefferson Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891722377 PECOS PAC ID: 0446151989 Enrollment ID: O20040116000736 |
News Archive
For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected.
Catching cancer early can make all the difference for successful treatment. A common screening practice measures tumor growth with X-ray computed tomography, which takes a series of cross-section images of the body.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.
BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
› Verified 5 days ago
| Entity Name | Potomac Valley Hospital Of Wva, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316054919 PECOS PAC ID: 8123917788 Enrollment ID: O20040311001344 |
News Archive
For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected.
Catching cancer early can make all the difference for successful treatment. A common screening practice measures tumor growth with X-ray computed tomography, which takes a series of cross-section images of the body.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.
BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
› Verified 5 days ago
| Entity Name | Potomac Valley Hospital Of Wva, Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1912979873 PECOS PAC ID: 8123917788 Enrollment ID: O20061104000290 |
News Archive
For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected.
Catching cancer early can make all the difference for successful treatment. A common screening practice measures tumor growth with X-ray computed tomography, which takes a series of cross-section images of the body.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.
BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
› Verified 5 days ago
| Entity Name | West Virginia Emergency Physicians Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952776379 PECOS PAC ID: 7618270323 Enrollment ID: O20160128002708 |
News Archive
For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected.
Catching cancer early can make all the difference for successful treatment. A common screening practice measures tumor growth with X-ray computed tomography, which takes a series of cross-section images of the body.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.
BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles K Kirkland, DO 812 Gorman Ave, Elkins, WV 26241-3181 Ph: (304) 636-3300 | Dr Charles K Kirkland, DO 812 Gorman Ave, Elkins, WV 26241-3181 Ph: (304) 636-3300 |
News Archive
For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected.
Catching cancer early can make all the difference for successful treatment. A common screening practice measures tumor growth with X-ray computed tomography, which takes a series of cross-section images of the body.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.
BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
› Verified 5 days ago
Dr. Timothy S Sears, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 Fax: 304-637-3435 | |
Dr. John M Logar, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 Fax: 304-637-3435 | |
Dr. Jacob Bryant Barkley, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 | |
Joseph R Contarino, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 Fax: 304-637-3441 | |
Dr. John S Veach, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 Fax: 304-637-3435 | |
Dr. Farukh A Khan, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Pleasant Ave, Suite1, Elkins, WV 26241 Phone: 304-636-5426 Fax: 304-636-2255 |